<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02699125</url>
  </required_header>
  <id_info>
    <org_study_id>guanhctz</org_study_id>
    <nct_id>NCT02699125</nct_id>
  </id_info>
  <brief_title>Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic</brief_title>
  <acronym>guanhctz</acronym>
  <official_title>A Placebo Controlled Double Blinded Crossover Study of the Antihypertensive Efficacy of Guanfacine vs Hydrochlorothiazide in Obstructive Sleep Apnea (OSA) Associated Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients who have obstructive sleep apnea (OSA) frequently stop breathing while they sleep.&#xD;
      They often develop high blood pressure. We are not sure what drug is best to treat the high&#xD;
      blood pressure. This study will give the patients guanfacine or hydrochlorothiazide (HCTZ)&#xD;
      for 6 weeks after 2 weeks of placebo. The blood pressure response will be evaluated by 24&#xD;
      hour monitoring.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a blinded crossover study measuring the antihypertensive efficacy of guanfacine vs&#xD;
      HCTZ in up to 34 subjects. Subjects with an apnea-hypopnea index (AHI) &gt; 10 and hypertension&#xD;
      can enter the study. Hypertension is defined as a systolic blood pressure (SBP) &gt; 140 or a&#xD;
      diastolic blood pressure (DBP) &gt; 90 on the average of three seated blood pressure&#xD;
      measurements or a history of medical therapy for hypertension. Subjects who have tried and&#xD;
      abandoned continuous positive airway pressure (CPAP) therapy for sleep apnea are eligible for&#xD;
      this study. All others will be advised that CPAP is preferred treatment for sleep apnea and&#xD;
      are eligible only if they decline CPAP or use it for too short a time at night to be&#xD;
      effective.&#xD;
&#xD;
      Then patients will have their antihypertensive drugs tapered off and receive single blind&#xD;
      placebo for two weeks. After that, all subjects receive guanfacine or HCTZ for six weeks with&#xD;
      a full evaluation at that time. Subjects are crossed over to HCTZ 12.5 mg for 2 weeks&#xD;
      followed by HCTZ 25 mg for 4 more weeks Guanfacine 1mg will be taken daily at bedtime for 2&#xD;
      weeks and then as a dose of 2 mg for the remaining 4 weeks. Subjects will receive a telephone&#xD;
      call at the time of increased dosage as a reminder. Blood, urine and 24-hour blood pressure&#xD;
      measurements, hemodynamic measurements, questionnaires and drug accountability are measured&#xD;
      in the same manner toward at the the end of placebo and each drug treatment. The entire study&#xD;
      will take 14 weeks, although each study period may be lengthened by one week if necessary for&#xD;
      the convenience of the subject's personal schedule.&#xD;
&#xD;
      Patients will provide blood pressure readings from their home monitor or in clinic and will&#xD;
      not have the dose increased if they have systolic blood pressure below 105 mm Hg or side&#xD;
      effects, such as excessive somnolence, drowsiness, or depression, suggesting that an&#xD;
      increased dose might worsen side effects&#xD;
&#xD;
      At the end of each treatment period, subjects will undergo noninvasive hemodynamic testing.&#xD;
      Ultrasound will be used to measure aortic diameter and blood velocity in the ascending aorta&#xD;
      in order to better estimate cardiac output. Then, finger plethysmography will be used to&#xD;
      acquire beat-to-beat finger blood pressure and pulse rate. Beat-to-beat derived hemodynamic&#xD;
      variables will be calculated by a model flow algorithm (e.g. brachial artery flow, stroke&#xD;
      volume, cardiac output, ejection time, blood pressure rate of change, peripheral resistance).&#xD;
      Applanation tonometry will be used to obtain pulse wave velocity and central arterial&#xD;
      pressure. ECG will be recorded with standard ECG leads to determine heart rate variability in&#xD;
      both time and frequency domains. Spontaneous baroreflex will be determined from beat-to-beat&#xD;
      changes in blood pressure and pulse pressure interval. Forearm reactive hyperemia will be&#xD;
      used to quantify endothelial dysfunction during 4 minutes of post-ischemic change. Subjects&#xD;
      will then complete an Epworth Sleepiness Scale questionnaire (ESS) and a Functional Outcomes&#xD;
      of Sleep Questionnaire (FOSQ) to find whether they are drowsy in the daytime and if they feel&#xD;
      that they are compromised by not having adequate rest. Any adverse event will be recorded.&#xD;
      They are asked about any concurrent medication over the prior period, including prescription&#xD;
      medication, over the counter medication, and caffeine intake. Medication compliance is&#xD;
      evaluated by pill count. Those who fail to return their pill bottle are requested to bring it&#xD;
      in. Finally, a 24-hour ambulatory blood pressure monitor (ABPM) will be attached to&#xD;
      automatically collect blood pressure and heart rate values every 15 minutes during the wake&#xD;
      period and every 30 minutes during the sleep period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure</measure>
    <time_frame>At the end of 2 weeks of placebo therapy, at the end of 6 weeks of guanfacine therapy and at the end of 6 weeks of hydrochlorothiazide therapy.</time_frame>
    <description>The primary outcome measure is ambulatory systolic and diastolic blood pressure recorded once every 15 minutes during the day and once every 30 minutes during the sleep. The Outcome Measure Data Table present primary outcome as &quot;24-h&quot;, &quot;Wake&quot; and &quot;Sleep&quot; Period Systolic and Diastolic Blood Pressure after each of the following three interventions: Placebo, Guanfacine and Hydrochlorothiazide.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brachial Artery Flow Mediated Dilation</measure>
    <time_frame>At the end of 2 weeks of placebo therapy, at the end of 6 weeks of guanfacine therapy and at the end of 6 weeks of hydrochlorothiazide therapy.</time_frame>
    <description>Brachial Artery Flow Mediated Dilation is upper arm brachial artery dilation during the 3 minutes forearm reactive hyperemia following the release of the 5-minute forearm cuff occlusion.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Placebo, Guanfacine, Hydrochlorothyazide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Hydrochlorothyazide, Guanfacine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Guanfacine</intervention_name>
    <description>Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.</description>
    <arm_group_label>Placebo, Guanfacine, Hydrochlorothyazide</arm_group_label>
    <arm_group_label>Placebo, Hydrochlorothyazide, Guanfacine</arm_group_label>
    <other_name>Tenex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks</description>
    <arm_group_label>Placebo, Guanfacine, Hydrochlorothyazide</arm_group_label>
    <arm_group_label>Placebo, Hydrochlorothyazide, Guanfacine</arm_group_label>
    <other_name>Hydrodiuril</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients ranging from 20 - 80 years&#xD;
&#xD;
          2. Body mass index (BMI) of 20-38 to include the typical obese OSA patients and avoid the&#xD;
             practical difficulties in blood drawing from the massively obese&#xD;
&#xD;
          3. Hypertension with blood pressures &gt; 140/90 but less than 180/105 mmHg.&#xD;
&#xD;
          4. Apnea-hypopnea index above 10&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Receiving medications other than anti-hypertensives known to influence the sympathetic&#xD;
             nervous system, sleep medicines (including heavy alcohol use) or drugs with adverse&#xD;
             interactions with study medication.&#xD;
&#xD;
          2. Women who have premenstrual syndrome, or those who are pregnant or capable of&#xD;
             pregnancy and unwilling to use effective non-hormonal contraception&#xD;
&#xD;
          3. Shift workers or have symptoms of narcolepsy, restless legs syndrome or insomnia, in&#xD;
             order to minimize confounding effects of other sleep disorders&#xD;
&#xD;
          4. Have apneas which are primarily central&#xD;
&#xD;
          5. Have sleep fragmentation caused by syndromes such as chronic pain or movement&#xD;
             disorders&#xD;
&#xD;
          6. Have diseases such as asthma or chronic obstructive pulmonary disease that compromises&#xD;
             respiration.&#xD;
&#xD;
          7. Have known coronary or cerebral vascular disease, history of arrhythmias,&#xD;
             cardiomyopathy, history of psychosis, current alcohol or drug abuse.&#xD;
&#xD;
          8. Have any contraindications to any study materials, such as heart block.&#xD;
&#xD;
          9. Have secondary hypertension&#xD;
&#xD;
         10. Have creatinine levels above 2.5 mg %, more than 1+ proteinuria by dipstick, hematuria&#xD;
             or electrolyte disorders.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael G. Ziegler, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD</affiliation>
  </overall_official>
  <reference>
    <citation>Ziegler MG, Milic M, Sun P. Antihypertensive therapy for patients with obstructive sleep apnea. Curr Opin Nephrol Hypertens. 2011 Jan;20(1):50-5. doi: 10.1097/MNH.0b013e3283402eb5. Review.</citation>
    <PMID>21326007</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 26, 2016</study_first_submitted>
  <study_first_submitted_qc>February 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2016</study_first_posted>
  <results_first_submitted>July 15, 2020</results_first_submitted>
  <results_first_submitted_qc>November 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 4, 2020</results_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Michael G. Ziegler</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Guanfacine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>405 participants were screened for eligibility.</recruitment_details>
      <pre_assignment_details>41 participant was enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Then Guanfacine, Then Hydrochlorothiazide</title>
          <description>Participants first received Placebo for 2 weeks. They then received guanfacine 1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks. They then received hydrochlotothyazide 12.5 mg for 2 weeks followed by hydrochlorothyazied 25 mg for 4 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Hydrochlorothiazide Then Guanfacine.</title>
          <description>Participants first received Placebo for 2 weeks. They then received hydrochlotothyazide 12.5 mg for 2 weeks followed by hydrochlorothyazied 25 mg for 4 weeks. They then received guanfacine 1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Placebo</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>First Intervention (6 Weeks).</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (6 Weeks).</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analyzed Baseline population for the primary outcome (21) and secondary outcome (18) is not consistent with the Overall Number of Baseline (Placebo) Participants (34) in the Participant Flow Module because (13) and (16) participants respectfully were excluded from the analysis due to either missing data and/or low quality ultrasound images.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>&quot;Placebo&quot; column have 6 rows of baseline Primary Outcome Values: &quot;24-h&quot;, &quot;Wake&quot; and &quot;Sleep&quot; Systolic and Diastolic Blood Pressure. &quot;Placebo&quot; column also have 1 row of baseline Secondary Outcome Value: Brachial Artery Flow Mediated Dilation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure</title>
          <description>Systolic Blood Pressure and Distolic Blood Pressure recorded during the Overall 24-h Period, every 15 minutes during the Wake Period and every 30 minutes during the Sleep Period.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>24-h systolic blood pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-h diastolic blood pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wake systolic blood pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wake diastolic blood pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep systolic blood pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep diastolic blood pressure</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Brachial Artery Flow Mediated Dilation</title>
          <description>Brachial Artery Flow Mediated Dilation is the maximal right brachial artery dilation during the reactive hyperemia following the release of the 5-minute cuff occlusion of the right forearm.</description>
          <population>The Overall Number of Participants Analyzed (18) differs from the Overall Number of Baseline Participants (21) because brachial artery flow mediated dilation data for 3 participants were excluded due to low quality of the ultrasound images.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.5" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure</title>
        <description>The primary outcome measure is ambulatory systolic and diastolic blood pressure recorded once every 15 minutes during the day and once every 30 minutes during the sleep. The Outcome Measure Data Table present primary outcome as &quot;24-h&quot;, &quot;Wake&quot; and &quot;Sleep&quot; Period Systolic and Diastolic Blood Pressure after each of the following three interventions: Placebo, Guanfacine and Hydrochlorothiazide.</description>
        <time_frame>At the end of 2 weeks of placebo therapy, at the end of 6 weeks of guanfacine therapy and at the end of 6 weeks of hydrochlorothiazide therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Hydrochlorothyazide</title>
            <description>Hydrochlorothyazide 12.5 mg for 2 weeks followed by hydrochlorothyazide 25 mg for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>24-h, Wake and Sleep Period Systolic and Diastolic Blood Pressure</title>
          <description>The primary outcome measure is ambulatory systolic and diastolic blood pressure recorded once every 15 minutes during the day and once every 30 minutes during the sleep. The Outcome Measure Data Table present primary outcome as &quot;24-h&quot;, &quot;Wake&quot; and &quot;Sleep&quot; Period Systolic and Diastolic Blood Pressure after each of the following three interventions: Placebo, Guanfacine and Hydrochlorothiazide.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24-h systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" spread="4.2"/>
                    <measurement group_id="O2" value="133" spread="2.9"/>
                    <measurement group_id="O3" value="136" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24-h diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="2.5"/>
                    <measurement group_id="O2" value="81" spread="2"/>
                    <measurement group_id="O3" value="83" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wake systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" spread="4.4"/>
                    <measurement group_id="O2" value="137" spread="3.1"/>
                    <measurement group_id="O3" value="139" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wake diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="2.7"/>
                    <measurement group_id="O2" value="84" spread="1.9"/>
                    <measurement group_id="O3" value="86" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136" spread="4.3"/>
                    <measurement group_id="O2" value="124" spread="2.6"/>
                    <measurement group_id="O3" value="130" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="2.4"/>
                    <measurement group_id="O2" value="73" spread="2.3"/>
                    <measurement group_id="O3" value="76" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brachial Artery Flow Mediated Dilation</title>
        <description>Brachial Artery Flow Mediated Dilation is upper arm brachial artery dilation during the 3 minutes forearm reactive hyperemia following the release of the 5-minute forearm cuff occlusion.</description>
        <time_frame>At the end of 2 weeks of placebo therapy, at the end of 6 weeks of guanfacine therapy and at the end of 6 weeks of hydrochlorothiazide therapy.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo for 2 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Guanfacine</title>
            <description>Guanfacine 1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Hydrochlorothiazide</title>
            <description>Hydrochlorothyazide 12.5 mg for 2 weeks followed by hydrochlorothyazide 25 mg for 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Brachial Artery Flow Mediated Dilation</title>
          <description>Brachial Artery Flow Mediated Dilation is upper arm brachial artery dilation during the 3 minutes forearm reactive hyperemia following the release of the 5-minute forearm cuff occlusion.</description>
          <units>percentage of the preoclussion diameter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="0.8"/>
                    <measurement group_id="O2" value="8.4" spread="1.1"/>
                    <measurement group_id="O3" value="4.9" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo for 2 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Guanfacine</title>
          <description>Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.&#xD;
Guanfacine: Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Hydrochlorothiazide</title>
          <description>Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.&#xD;
Hydrochlorothiazide: Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael G. Ziegler, M.D.</name_or_title>
      <organization>University of California San Diego</organization>
      <phone>619 543 2885</phone>
      <email>mziegler@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

